Scancell Holdings PLC (LON:SCLP) has said it would either develop its cancer immunotherapy in-house or with a new partner after ending a clinical development tie-up with Cancer Research UK (CRUK).
The decision to curtail clinical development work on Scancell target SCIB2 followed a re-assessment of the charity’s collaboration model in the wake of the coronavirus pandemic, the company said.
CRUK was due to fund and sponsor a phase I/II trial of SCIB2 in combination with a checkpoint inhibitor drug in patients with solid tumours.
The product rights will now revert to Scancell with no further commercial obligations to CRUK, Scancell said.
In a statement, Scancell chief executive, Dr Cliff Holloway, added: "We have enjoyed working with the team at Cancer Research UK but will now explore further options to advance the SCIB2 programme which we believe has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours."